2 unchanged sentences
Filed or Furnished Herewith
−Removed: Restated Certificate of Incorporation
−Removed: Restated Bylaws
−Removed: Form of Indemnity Agreement by and between Nurix Therapeutics and each of its directors and executive officers
−Removed: 2020 Equity Incentive Plan and forms of award agreements
−Removed: July 20, 2020
−Removed: 2020 Employee Stock Purchase Plan and forms of award agreements
−Removed: July 20, 2020
−Removed: Employment Agreement, dated July 15, 2020, by and between the Registrant and Arthur T.
−Removed: July 20, 2020
−Removed: Employment Agreement, dated July 15, 2020, by and between the Registrant and Pierre Beaurang
−Removed: July 20, 2020
−Removed: Employment Agreement, dated July 15, 2020, by and between the Registrant and Gwenn Hansen
−Removed: July 20, 2020
−Removed: Letter Agreement, dated June 15, 2020, by and between the Registrant and Arthur T.
−Removed: July 20, 2020
+Added: First Amendment to Collaboration and License Agreement, dated January 6, 2021, by and between the Registrant and Genzyme Corporation
+Added: February 16, 2021
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
−Removed: Certification of Principal Executive Officer Pursuant to 18 U.S.C.
−Removed: Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of Principal Financial Officer Pursuant to 18 U.S.C.
+Added: Certification of Principal Executive Officer and Principal Financial and Accounting Officer Pursuant to 18 U.S.C.
Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
5 unchanged sentences
XBRL Taxonomy Extension Presentation Linkbase Document
−Removed: The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Quarterly Report on Form 10-Q and are not deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
+Added: The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-Q and are not deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: October 14, 2020
+Added: NURIX THERAPEUTICS, INC.
+Added: April 13, 2021
/s/ Arthur T.
Sands, M.D., Ph.D.
−Removed: President and Chief Executive Officer
+Added: President, Chief Executive Officer and Director
(Principal Executive Officer)
−Removed: October 14, 2020
+Added: April 13, 2021
/s/ Hans van Houte
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.